Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment

(2020) Nicolas Palaskas et al.   Journal of the American Heart Association

Clinical Significance of High-Mobility Group Box 1 Protein (HMGB1) and Nod-Like Receptor Protein 3 (NLRP3) in Patients with Ulcerative Colitis

(2020) YanMin Chen et al.   MEDICAL SCIENCE MONITOR

Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells

(2020) Margherita Passariello et al.   Cancers

Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

(2020) Fausto Petrelli et al.   Cancers

Boswellic acid has anti‐inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells

(2019) Manlio Barbarisi et al.   PHYTOTHERAPY RESEARCH

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab

(2019) V. Quagliariello et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma

(2019) Changhoon Choi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges

(2019) Roberto Martin Huertas et al.   Cancer Management and Research

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data

(2019) Pauline du Rusquec et al.   Cancer Management and Research

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

(2019) Alfredo Addeo et al.   Frontiers in Oncology

Low doses of Bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of Doxorubicin in cardiomyoblasts

(2019) V. Quagliariello et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

(2019) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

(2019) Joe-Elie Salem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders

(2019) Arnaud Jannin et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management

(2019) Yu-Wen Zhou et al.   Frontiers in Pharmacology

Pharmacological Inhibitors of the NLRP3 Inflammasome

(2019) Ayesha Zahid et al.   Frontiers in Immunology

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

(2019) Rina Hui et al.   LANCET ONCOLOGY

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

(2018) Xuexiang Du et al.   CELL RESEARCH

Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue

(2018) Gilda Varricchi et al.   CURRENT MEDICINAL CHEMISTRY

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

(2018) Yared Hailemichael et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer immunotherapy beyond immune checkpoint inhibitors

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies

(2018) Emanuele Sasso et al.   mAbs

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine

(2018) Claudia De Lorenzo et al.   OncoTargets and Therapy

NLRP3: A Novel Mediator in Cardiovascular Disease

(2018) Wenyi Zhou et al.   Journal of Immunology Research

IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction

(2018) Benjamin W. Van Tassell et al.   Circulation-Heart Failure

Immune checkpoint inhibitors and cardiovascular toxicity

(2018) Alexander R Lyon et al.   LANCET ONCOLOGY

Immune-related adverse events of immune checkpoint inhibitors: a brief review

(2018) G. Myers   Current Oncology

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

(2018) Cheng Xu et al.   BMJ-British Medical Journal

Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormone-Responsive Human Breast Cancer

(2017) Vincenzo Quagliariello et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

(2017) Michele Maio et al.   LANCET ONCOLOGY

Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab

(2016) Tomonori Tadokoro et al.   Circulation-Heart Failure

Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer

(2016) Gillian M. Keating   DRUGS

Curcumin bioavailability from oil in water nano-emulsions: In vitro and in vivo study on the dimensional, compositional and interactional dependence

(2016) Raffaele Vecchione et al.   JOURNAL OF CONTROLLED RELEASE

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases

(2016) Agnieszka Wasilewska et al.   Postepy Dermatologii i Alergologii

MyD88-dependent Toll-like receptor 4 signal pathway in intervertebral disc degeneration

(2016) Chuqiang Qin et al.   Experimental and Therapeutic Medicine

Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse

(2015) Carlo Marchetti et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

(2015) Benjamin P Geisler et al.   Journal for ImmunoTherapy of Cancer

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

(2014) Lei Lu et al.   Journal of Translational Medicine

The inflammatory response in myocardial injury, repair and remodelling

(2014) Nikolaos G. Frangogiannis   Nature Reviews Cardiology

Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells

(2014) C. D'Avino et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Ipilimumab-induced acute severe colitis treated by infliximab

(2013) Cecile Pagès et al.   MELANOMA RESEARCH

Inflammatory Cytokines in Heart Failure: Mediators and Markers

(2012) Lars Gullestad et al.   CARDIOLOGY

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours

(2011) M Borriello et al.   BRITISH JOURNAL OF CANCER

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

(2011) Zahra Hanaizi et al.   EUROPEAN JOURNAL OF CANCER

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours

(2010) T Gelardi et al.   BRITISH JOURNAL OF CANCER

Speckle tracking echocardiography in the assessment of mouse models of cardiac dysfunction

(2009) Yu Peng et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY